



Australian Precision Oncology Symposium (APOS) 2025



Omico

Cancer
meets its match






The Coming of Age of Precision Oncology

We warmly invite you to exclusively attend the Australian Precision Oncology Symposium 2025!

APOS 25 Theme: The Coming of Age of Precision Oncology.

APOS 25 will showcase a pivotal moment in cancer care, as precision oncology moves from theory to transformative practice. Designed for Australian oncology professionals—including oncologists, researchers, pathologists, and members of the life science and advocacy sectors—APOS 25 is set to be an impactful gathering of thought leaders in precision oncology.



Date: Friday 7 – Saturday 8 March 2025



Mode: Face to Face & Online



Location:

Venue – John Niland Scientia Building, UNSW Kensington campus Kensington, NSW, 2052

Address – G19 Library Road, Kensington

Key Dates

Registrations Close – Friday, 1 March 2025

What to expect at APOS 25?

The symposium will bring together renowned international and local speakers, providing a rich spectrum of perspectives on the latest advancements in precision oncology. Attendees will engage with experts, explore groundbreaking research, and foster meaningful professional connections.

Program highlights include:

- **Cutting Edge Therapeutics:** Updates on clinical trials of emerging important precision therapies.
- **Technology Advances:** Topics include blood-based multi-cancer early detection tests, homologous recombination deficiency, screening for antibody drug conjugates, synthetic lethality, and more.
- **Real World Data Insights:** Focused on long-term care and survivorship in the AYA (adolescent and young adult) space, quality of life in precision oncology settings, and emerging trends in proteomics.

- **Clinical Impact:** Discover what's on the pharmaco-genomics horizon relevant to management of cancer patients.
- **Live Molecular Oncology Board:** A unique, interactive session providing for real-time insights on translating precision oncology from theory to real-world application.

For those attending in person, this Symposium offers a unique networking opportunity, fostering collaboration and interaction among participants. Attendees will have the chance to connect with experts in the field, share insights, and build valuable professional relationships, enhancing the overall experience and impact of the event.

For virtual participants, you have the flexibility to access any or all of the five sessions in the program, tailoring your experience to focus on the topics most pertinent to your specific areas of interest.

APOS 25 Speaker Faculty.

APOS 25 promises to present an exciting array of speakers, featuring two renowned international experts who will bring their global insights to the event.



Professor Mark Middleton, UK

Head of the Department of Oncology, University of Oxford, UK

Mark is Co-Director of Oxford Cancer and Head of Oncology at the University of Oxford, where he founded the Early Phase Clinical Trials Unit. His clinical and research interests are in new drug development, the treatment of upper GI tumours and the early detection of new and relapsing cancers.

He has been Chief or Principal Investigator on >100 trials and closely involved in the development of new therapies including DNA repair, immune checkpoint and kinase inhibitors, ImmTACs and oncolytic viruses. Mark trained in Medicine at the Universities of Cambridge and Oxford, and in Oncology at the Christie Hospital and University of Manchester.



Dr Raoul Reulen PhD, UK

Associate Professor, Cancer Epidemiology, University of Birmingham, UK

Raoul specialises in the long-term health risks faced by childhood, adolescent, and young adult cancer survivors. His research focuses on the British Childhood Cancer Survivor Study (BCCSS) and the Teenage and Young Adult Cancer Survivor Study (TYACSS), large-scale cohorts tracking health outcomes in over 235,000 survivors.

These studies provide key insights into late mortality, secondary cancers, cardiovascular disease, and other long-term effects of cancer treatment. Internationally, Raoul has contributed to major collaborative studies, including the EU-funded PanCareSurFup project, which examined cancer risks across 12 European countries.

In addition, a carefully curated selection of respected Australian professionals will also contribute to the program.



Professor David Thomas



A/Prof Oliver Klein



Dr Timothy Humphries



Dr Min Li Huang



Dr Sam Harris



Dr Malaka Ameratunga



Dr Subo Thavaneswaran



A/Prof Anna Brown



Dr Maya Kansara



Professor Hilda Pickett



Dr Milita Zaheed



A/Prof Kathy Tucker



Professor Damien Kee



Professor Hui Gan



A/Prof Catherine Mitchell



Dr Noemi Fuentes-Bolanos



Dr Ronald Chan



Dr John Grady



Dr Amy Body



Dr Greg Gaughran



Dr Kosar Hooshmand

APOS 25 Sponsors.



We would like to express our gratitude to our dedicated sponsors for their generous support of APOS 25.

Their contributions will play a pivotal role in making this event a success. We are proud to showcase our sponsors as part of this event and look forward to continuing our collaboration in the future.



Silver Sponsors:



Bronze Sponsors:



APOS 25 Program.

Friday, 7 March 2025

Session 1: Molecular therapeutics – Chaired by Dr Greg Gaughran

1:00 – 1:10pm	Welcome and opening remarks Professor David Thomas, Chief of Science and Strategy, Omico Welcome to country Aunty Maxine Ryan, La Perouse Aboriginal Community
1:10 – 1:45pm	MoST CIRCUIT – Immunotherapy succeeds in rare cancers Associate Professor Oliver Klein – 25min talk, 10min Q&A
1:45 – 2:05pm	Results from the phase 1 part of the PYNNACLE study assessing Rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation Dr Amy Body – 15min talk, 5min Q&A
2:05 – 2:25pm	Clinical results from a phase 1 trial of PRT3789, a first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation Dr Timothy Humphries – 15min talk, 5min Q&A
2:25 – 2:35pm	MAT2A inhibitor trial in progress Dr Malaka Ameratunga – 7min talk, 3min Q&A
2:35 – 2:45pm	Prevalence of MTAP deletion in Australia Dr Sam Harris – 7min talk, 3min Q&A

Session 2: Transforming technologies – Chaired by Prof. David Thomas

3:15 – 3:50pm	Precision diagnostics: Multi-cancer early detection using ctDNA in the SYMPLIFY study Professor Mark Middleton – 25min talk, 10min Q&A
3:50 – 4:10pm	Beyond Ovarian Cancer: Navigating the Challenges of Expanding HRD Testing Associate Professor Anna Brown – 15min talk, 5min Q&A
4:10 – 4:30pm	Omico’s Screening Strategy for ADC/bispecific Ab Targets Dr Maya Kansara – 15min talk, 5min Q&A
4:30 – 4:50pm	Targeting telomere replication stress to treat ALT cancers Professor Hilda Pickett– 15min talk, 5min Q&A
4:50 – 5:20pm	Panel: Emerging technologies in precision oncology – Chaired by Prof. David Thomas Prof Mark Middleton, A/Prof Anna Brown, Prof Hilda Pickett, Dr Maya Kansara – 30 min talk & Q&A

Saturday, 8 March 2025

Session 3: Cancer in the young and survivorship – Chaired by A/Prof. Mandy Ballinger

9:00 – 9:10am	Opening remarks A/Professor Mandy Ballinger, Head of Cohorts, Omico Honouring International Women’s Day Christine Cockburn, CEO, Rare Cancers Australia
9:10 – 9:45am	Long-term adverse health outcomes in survivors of adolescent and young adult cancer Dr Raoul Reulen – 25min talk, 10min Q&A
9:45 – 10:05am	Novel omics strategies for personalised risk management Professor David Thomas – 15min talk, 5min Q&A
10:05 – 10:25am	Germline cancer predisposition in the young Dr Milita Zaheed – 15min talk, 5min Q&A
10:25 – 10:45am	Panel: The changing face of germline cancer genetics Professor David Thomas, Dr Milita Zaheed, A/Prof Kathy Tucker, Dr Noemi Fuentes-Bolanos – 20min talk & Q&A

Session 4: From research to clinical impact – Chaired by Dr Min Li Huang

11:10 – 11:40am	The evolving role of comprehensive genomic profiling in tumour diagnosis and classification. A/Prof Catherine Mitchell – 20min talk, 10min Q&A
11:40 – 12:00pm	Detecting what’s missing: Sensitivity trade-offs in liquid biopsies versus prior NGS panels and comparator CGP tissue biopsies Dr Greg Gaughran – 15min talk, 5min Q&A
12:00 – 12:20pm	Pharmacogenetics and public health impact Dr Kosar Hooshmand – 15min talk, 5min Q&A
12:20 – 12:40pm	Impact of matched treatment – looking beyond survival Dr Ronald Chan – 15min talk, 5min Q&A

Session 5: Live molecular oncology board – Chaired by Prof. David Thomas

1:30 – 2:30pm	Individual cases from molecular pathology to treatment recommendations Prof Hui Gan, Prof Damien Kee, Dr John Grady, Dr Min Li Huang, Dr Milita Zaheed, Dr Subo Thavaneswaran – 60min talk & Q&A
2:30 – 2:45pm	Close Professor David Thomas



Contact.

Should you have any questions or require further information, please contact:

Fidan Rasimoglou - Marketing Manager, Omico
Email: f.rasimoglou@omico.org.au

[Omico.com.au](https://omico.com.au)

Follow us @OmicoAustralia:

f **@** **in** **X**

©Copyright 2025. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not for profit company limited by guarantee. Hilmer building (E10), Union Rd, UNSW, Kensington, NSW, 2052.